Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$6.51 +1.6%	$6.21	$4.47 ▼ $35.98	$7.16M	0.9	100,025 shs	8,492 shs
CLNN Clene	$3.76 -4.1%	$3.33	$2.28 ▼ $7.40	$33.78M	0.49	90,535 shs	60,601 shs
DARE Dare Bioscience	$2.37 -9.9%	$2.93	$2.35 ▼ $4.60	$20.97M	1.2	36,292 shs	101,472 shs
GDTC CytoMed Therapeutics	$2.28 -0.9%	$2.25	$1.20 ▼ $4.05	N/A	-0.33	78,258 shs	271 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	0.00%	+14.21%	+3.25%	+5.00%	-69.13%
CLNN Clene	0.00%	-12.15%	+20.51%	+22.08%	-47.22%
DARE Dare Bioscience	0.00%	-15.96%	-17.42%	-17.99%	-41.24%
GDTC CytoMed Therapeutics	0.00%	+1.38%	-1.72%	+3.64%	+9.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLM Apollomics	0.8935 of 5 stars	0.0	5.0	3.3	0.0	0.0
CLNN Clene	2.9999 of 5 stars	3.6	2.0	3.3	2.5	0.6
DARE Dare Bioscience	2.4934 of 5 stars	3.3	5.0	3.3	0.0	0.0
GDTC CytoMed Therapeutics	2.7151 of 5 stars	3.5	5.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	0.00	N/A	N/A	N/A
CLNN Clene	3.17	Buy	$40.00	963.83% Upside
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	406.33% Upside
GDTC CytoMed Therapeutics	3.00	Buy	$5.00	119.30% Upside

Current Analyst Ratings Breakdown

Latest APLM, DARE, GDTC, and CLNN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/1/2025	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$1.49M	4.81	N/A	N/A	$4.48 per share	1.45
CLNN Clene	$340K	99.31	N/A	N/A	($1.06) per share	-3.55
DARE Dare Bioscience	$10K	2,097.45	N/A	N/A	($0.69) per share	-3.43
GDTC CytoMed Therapeutics	$50K	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$53.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	-1,106.30%	-105.11%	8/6/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-8.14%	8/11/2025 (Estimated)
GDTC CytoMed Therapeutics	-$1.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/28/2025 (Estimated)

Latest APLM, DARE, GDTC, and CLNN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
3/31/2025	Q4 2024	DARE Dare Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	1.39	1.39
CLNN Clene	N/A	1.36	1.36
DARE Dare Bioscience	N/A	0.56	0.56
GDTC CytoMed Therapeutics	0.05	9.89	9.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
CLNN Clene	23.28%
DARE Dare Bioscience	6.70%
GDTC CytoMed Therapeutics	0.04%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
CLNN Clene	35.30%
DARE Dare Bioscience	4.00%
GDTC CytoMed Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	1.10 million	N/A	Not Optionable
CLNN Clene	100	8.98 million	5.81 million	Optionable
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
GDTC CytoMed Therapeutics	N/A	N/A	N/A	Not Optionable

APLM, DARE, GDTC, and CLNN Headlines

Recent News About These Companies

CytoMed Therapeutics Schedules AGM for June 2025

May 16, 2025 | tipranks.com

CytoMed Therapeutics Reports 2024 Financial Results and Clinical Progress

May 7, 2025 | tipranks.com

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial ResultsÂ and Provides Clinical and Corporate Updates

April 28, 2025 | globenewswire.com

CytoMed Therapeutics Limited Shares 2024 Accomplishments and Outlook for 2025 in Shareholder Letter

February 6, 2025 | quiverquant.comQ

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

February 6, 2025 | globenewswire.com

CytoMed Therapeutics Expands Leadership Amid Strategic Growth

December 5, 2024 | tipranks.com

CytoMed Therapeutics Limited (GDTC)

July 19, 2024 | finance.yahoo.com

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

July 17, 2024 | globenewswire.com

CytoMed Therapeutics Ltd GDTC

March 27, 2024 | morningstar.comM

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

March 20, 2024 | finance.yahoo.com

CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

March 18, 2024 | finanznachrichten.de

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

March 18, 2024 | markets.businessinsider.com

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

March 18, 2024 | globenewswire.com

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

March 4, 2024 | globenewswire.com

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

August 15, 2023 | finance.yahoo.com

CytoMed Therapeutics Ltd (GDTC)

August 8, 2023 | investing.com

Insiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51m

August 8, 2023 | finance.yahoo.com

CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology

August 8, 2023 | finance.yahoo.com

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

August 8, 2023 | finance.yahoo.com

Why Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?

July 11, 2023 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, DARE, GDTC, and CLNN Company Descriptions

Apollomics NASDAQ:APLM

$6.51 +0.10 (+1.56%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$6.50 -0.01 (-0.23%)

As of 06/27/2025 07:58 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Clene NASDAQ:CLNN

$3.76 -0.16 (-4.08%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.70 -0.06 (-1.73%)

As of 06/27/2025 07:49 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Dare Bioscience NASDAQ:DARE

$2.37 -0.26 (-9.89%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.38 +0.01 (+0.63%)

As of 06/27/2025 07:01 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

CytoMed Therapeutics NASDAQ:GDTC

$2.28 -0.02 (-0.87%)

Closing price 06/27/2025 03:54 PM Eastern

Extended Trading

$2.28 0.00 (0.00%)

As of 06/27/2025 07:45 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time